D espite significant progress, depression remains a common and disabling condition that affects millions, leading to increased primary care visits and decreased productivity (Baune, Adrian, & Jacobi, 2007) . Both psychotherapy and antidepressant pharmacotherapy are evidence-based treatments recommended by experts and treatment guidelines (Gelenberg et al., 2010) . For those with more severe depression, pharmacotherapy is often required for recovery. However, inadequate response and lack of remission are common, and characterize treatmentresistant depression (TRD; Keitner and Mansfield, 2012) . The current pharmacopoeia available to clinicians is primarily based on modulation of serotonergic, noradrenergic, and dopaminergic transmission in the brain, with first line agents primarily consisting of selective serotonin reuptake inhibitors (SSRIs; Keitner & Mansfield, 2012) . As demonstrated by the STAR*D study, multiple trials of medications are frequently required to achieve remission, and despite this, about 35% of patients remain symptomatic after several successive interventions (Rush et al., 2006; Olin, Jayewardene, Bunker, & Moreno, 2012) . When monoamine modulating antidepressant medications do work, there is typically a delay of weeks before response is achieved. In those first few weeks, antidepressant treatment may increase risk of suicidal behavior, and possibly including completed suicide (Björkenstam et al., 2013) . With the lack of rapid response from existing medications, and indeed the apparent risk until such response, there is urgent need for development of rapid acting treatment alternatives for depression (Monteggia, Gideons, & Kavalali, 2013) . For severe depression, electroconvulsive therapy (ECT) is the only somatic intervention with the potential for more rapid treatment effect, however concern over adverse effects limit use. Alternative approaches utilizing direct electrical modulation, including repetitive transcranial magnetic stimulation (rTMS), trigeminal nerve stimulation, and deep brain stimulation (Cook, Espinoza, & Leuchter, 2014) as well as magnetic seizure therapy and vagal nerve stimulation (Wani, Trevino, Marnell, & Husain, 2013) are promising in terms of efficacy, but have not been shown consistently to have a more rapid onset of effect than pharmacotherapy.
Studies suggest a role for the glutamate system in regulation of mood (Skolnick et al., 1996; Matthews, has been generated from studies looking at the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine for this novel indication (Artigas, 2013; Mathew, Manji, & Charney, 2008) . Ketamine was developed in 1963, first tested on humans in 1964, and FDA approved for roles in anesthesia in 1970 (Reich et al., 1989; JHP Pharmaceuticals, 2009 ). It was not until 2000 that ketamine was concretely demonstrated in the literature to have antidepressant properties (Berman et al., 2000) . Ketamine has shown a large effect size, with onset on the order of hours, and duration of effect of approximately one week (Zarate et al., 2006) . Reduction in suicidal thoughts is further described, similarly within hours of administration (Price et al., 2009; Price et al., 2014) .
A significant limitation exists in that ketamine is only FDA-approved for intravenous (IV) or intramuscular (IM) use in induction or maintenance of anesthesia, making administration in less controlled settings difficult. While most studies on ketamine thus far have looked at longer IV infusions, other routes have shown promise for increasing patient access to ketamine (Larkin & Beautrais, 2011; Harihar, Dasari, & Srinivas, 2013; Lara, Bisol, & Munari, 2013; Lapidus et al., 2014; Iglewicz et al., 2014) .
This article reviews the extant literature regarding use of ketamine as an antidepressant, highlighting its role as a rapid acting agent for unipolar and bipolar depression. We report on and analyze efficacy, with additional attention to durability of response, improvement in suicidality, routes of administration, dosing protocols, and safety. Different stereoisomeric forms of ketamine are also reviewed given the possibility that one form may be associated with fewer dissociative effects. We conclude with recommendations for future study design as well as potential off-label use in less structured settings. Detailed discussions on the history and neuropharmacology of ketamine, and the glutamate theory of depression are not included; the reader is referred to previous publications on these topics (Domino et al., 2010; Krystal, Sanacora, & Duman, 2013; Caddy. Giaroli, White, Shergill, & Tracy, 2014; Naughton, Clarke, Olivia, Cryan, & Dinan, 2014) .
Materials and Methods

P
ubMed.gov was searched using the term "ketamine depression," with the filter of English language, through March 2015, yielding 1042 studies. Studies were excluded that did not investigate clinical use of ketamine in humans for treatment of depression, either unipolar or bipolar, or suicidality. Those utilizing ketamine as an anesthetic or augmenting agent for, or in combination with, ECT or rTMS were excluded, as were studies regarding the use of ketamine as an augmenting agent for psychotherapy, for purposeful alteration of consciousness, or in regards to ketamine misuse. The remaining articles were further reviewed for pertinent references. Data on depression response rates were combined and recalculated to include intent to treat (ITT) analysis, accounting for differences between rates reported in the studies and in this review. To assess for ongoing or planned studies a search of ClinicalTrials.gov was performed with the terms "ketamine depression." Results U sing the above search criteria, a total of 61 publications from PubMed.gov and 96 from ClinicalTrials.gov were identified for inclusion in this review.
Study population and methodology
Of these 61 studies, 46 utilized the IV route of administration, accounting for over 450 patients in total. A further 18 studies utilized IM, oral, intranasal, sublingual, or subcutaneous treatment in over 100 patients. Nearly all publications reported use of racemic ketamine, with only 13 patients in total receiving S-ketamine (Denk, Rewerts, Holsboer, ErhardtLehmann, & Turck, 2011; Paul, Schaaf, Padberg, Moller, & Frodl, 2009; Segmiller et al., 2013; Paslakis, Gilles, Meyer-Lindenberg, & Deuschle, 2010) . Most studies utilized only one administration of ketamine, though five open label investigations (OLI) and one randomized control trial (RCT) did assess multiple doses, from one to three times per week, for up to three weeks. The majority of publications reported on patients with unipolar depression, though bipolar depression was also represented in ten. Given the differences in presentation, etiology, and response between these two types of depression, these are considered separately. Save for a minority of case studies (Table 5 ; Suppl. Table 1) , articles utilized one or more validated depression rating scales, including the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery and Åsberg, 1979), Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) , Beck Depression Inventory (BDI; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) , or Clinical Global Impression scale (CGI; Guy et al., 1976) . The only study to report on the pediatric population utilized
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Ryan, Marta, & Koek ratings scales more specific to that population (Papolos, Teicher, Faedda, Murphy, & Mattis, 2013) . Studies of ketamine in hospice patients also utilized the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) (Table 5 ; Suppl. Table 1) . We focused on the categorical outcome of response-defined as >50% reduction-within 24 hours since this was most commonly the primary outcome measure referred to in the studies reviewed. Remission was not consistently reported, and was also variably defined. Notably, too, the majority of these studies were performed in patients with treatment resistance, and while definitions varied between studies, this typically was qualified by at least two, if not more, failed trials of adequate dose and duration antidepressant treatment. Some also included failure of ECT and only few described failure of adequate psychotherapy. To objectively assess such trials, many studies utilized the Antidepressant Treatment History Form (Sackeim, 2001) . Unless otherwise specified below, we accept the authors' descriptions of TRD. Of the studies employing ketamine IV infusions, most utilized racemic ketamine 0.5mg/kg over 40 minutes, with several more varying the duration from 30 to 60 minutes. For the sake of brevity, we abbreviate this protocol as KET in the rest of this document.
Efficacy From Single Infusions
The eight RCTs investigating IV ketamine included six crossover studies, all with saline placebo, and two parallel group designs, both with active controls (Table 1 ). All but one utilized a single ketamine infusion. Six were done in patients with unipolar depression and the other two in patients with bipolar depression. The larger of the two active control and blinded RCTs utilized midazolam and included 72 patients in a 2:1 ratio of ketamine : midazolam, all with treatment-resistant unipolar depression, who were discontinued from any concomitant medications. In the ketamine group, 64% responded at 24 hour follow-up, compared to 28% in the midazolam group (Murrough, Perez, Mathew, & Charney, 2013) . Response rate in the ketamine arm fell below 50% after day three. The other active control blinded RCT utilized ECT as the comparison condition, demonstrating a more rapid onset of action and greater response rates at 24 hours in the ketamine arm; KET elicited 78% response versus 11% with ECT (Ghasemi et al., 2013) . The other placebo controlled studies in unipolar depression generally recruited fewer patients, and found 24 hours outcomes of 45% with KET versus 2% with saline; and 4 hour outcomes of 29% versus 7% (Figure 1) .
Both studies of patients with bipolar depression were performed by the same group and found more rapid onset, but shorter duration, of benefit (Table 1) . Response was 58% in the first four hours, but by day one, half of the cohort no longer met this criterion (Figure 2 ). While studies in unipolar depression generally discontinued psychotropic medications and provided a washout period, those in bipolar depression maintained patients on therapeutic levels of mood stabilizers, either lithium or valproic acid, which may have had an effect on outcome.
Limitations in blinding and control selection are prevalent in all but Murrough et al. (2013) , who utilized midazolam as an active control. The trial with ECT as the active control (Ghasemi et al., 2013) did not appear to have had strict patient blinding, despite blinding of the treatment team. Valentine et al. (2011) was the opposite, with study personnel being aware of experimental conditions. Other studies utilized a saline placebo, but the apparent ease in recognition of dissociative effects likely sabotaged the blind.
Seventeen OLIs describe outcomes in unique depressed patients after KET, of which sixteen were principally in unipolar depression (Table 2) . Nearly half of the over 250 unipolar depression patients, 95% of whom were categorized as TRD, responded within 4-6 hours after KET (Figure 3) . At 24 hours, the overall response rate increased to 59% and then gradually declined with time. While 4 week outcomes were only available for 47 individuals, the 21% response rate after a single infusion is remarkable in light of the high degree of treatment resistance. Each open-label trial was focused on some aspect of KET besides acute antidepressant efficacy per se, with several valuable findings. demonstrated robust, but short-lived (< 3 days) antidepressant effects of standard dose KET in an Indian population. Ibrahim et al. (2011) demonstrated that a history of non-response to ECT was not associated with a reduced likelihood of response to KET in TRD. a potential biomarker, demonstrating that non-alcoholdependent MDD subjects with a family history of alcoholism had a substantially greater likelihood of response to KET than those without. Luckenbaugh et al. (2012) reported similar findings from a posthoc analysis of RCT data (Diazgranados et al., 2010a; Zarate et al., 2012) . Both Mathew et al. (2010) and Ibrahim et al. (2012) failed to demonstrate benefits from randomization to riluzole over placebo during planned month-long follow-up treatment after response to openlabel KET. Finally, Larkin and Beautrais (2011) found administration of a lower total ketamine dose (0.2 mg/ kg), via IV bolus rather than slow infusion, permitted use in an emergency department setting by busy clinicians. While they reported cumulative remission of 71.4% in the first four hours, improved response in the subsequent two weeks must be interpreted in light of telephone follow up and naturalistic treatment, including inpatient care (this data omitted from the table).
The one OLI solely in patients with treatmentresistant bipolar depression demonstrated progressive decreases in mean HDRS score and increases in response (Rybakowski, Permoda-Osip, Skibinska, Adamski, & Bartkowska-Sniatkowska, 2013 ; Table 2 ). Response more than doubled from 24% at 1 day to 52% at 1 week, remaining stable for the duration of the two week long trial. Patients were maintained on a variety of mood stabilizing medications, although a limitation of the study is that subjects were tapered off of antidepressants as recently as 2 weeks prior to KET. This may potentially explain the large disparity in outcome data from the more rigorously designed RCTs.
Multidose Studies
One RCT and five OLIs assessed multiple sequential doses of IV ketamine (Table 3) . Of these, three utilized a regimen of thrice weekly infusions for two weeks. Another utilized up to four infusions, at a rate of two per week over two weeks, stopping once patients achieved remission. Only one study directly compared two different schedules: once weekly versus twice weekly infusions over the course of three weeks (Diamond et al., 2014) . All six noted either stable or increasing rates of response over subsequent infusions. The response rate for all subjects within 24 hours of their final infusion was 59%, though if the outlier is excluded (Diamond et al. 2014) , this increases to 74%. The majority of these studies also reported time to relapse after the final infusion, monitoring subjects over the subsequent 4 weeks or longer, however criteria for relapse varied from liberal (aan het to conservative (Shiroma et al., 2014) . Summing totals from these studies over each time point reveals 50% of patients no longer met response criteria between 7-10 days following the final infusion, which may potentially underestimate true benefit due to our conservative calculations (Figure 4) .
The one RCT compared three ketamine infusions with three bilateral ECT treatments over one week, finding 89% response rate after three ketamine infusions versus 67% with ECT (Ghasemi et al., 2013) . Regarding the five OLIs, all unique patients are represented in Murrough et al. (2013) , Rasmussen et al. (2013) , Shiroma et al. (2014) , and Diamond et al. (2014) . Response rates immediately after conclusion of the series of infusions were 71%, 60%, 79%, and 29%, respectively (ITT). Diamond et al. (2014) [7] Subjects overlap with .
[2] Responders were randomized to daily riluzole or placebo, but upon subsequent analysis differences determined to non-significant. * some studies did not report depression response at all time points.31/85 (36%) Response data was recalculated conservatively, accounting for differences from published data. Data from first infusions are also reported on tables 1 and 2 where appropriate.
[1] Patients overlap between studies.
[2] Three responders were started on venlafaxine as part of another study. All studies utilized 0.5mg/kg IV over 40 minutes except [3] over 100 minutes, [4] over 45 minutes.
[5] Calculation excluded aan het Rot et al. given these subjects are represented in Murrough et al.
the outlier. Altogether, studies yielded a 22% response rate approximately a month after conclusion of the course. In Murrough et al. (2013) , 17% remained responders over an additional 3 months follow-up, with only one receiving other medication in the interim. These authors also observed that initial nonresponders (at 4 hours after the first infusion) were four times less likely than initial responders to achieve response at the end of 6 infusions. Additionally, several studies noted that patients required up to two infusions before successfully achieving response (Rasmussen et al., 2013; Diamond et al., 2014) , suggesting that one infusion may be insufficient. Rasmussen et al. (2013) added to the literature by extending 0.5mg/kg infusions over 100 minutes (0.3 mg/kg/hr), the slower rate permitting use without presence of anesthesia personnel. Interestingly enough, the study with the lowest response rate was conducted in an ECT recovery room and found that several patients complained the setting was too noisy, chaotic, or distressing (Diamond et al., 2014) . Also notable is that this is the only study to use the BDI, a patient rated scale, as an outcome measure. The other study that was conducted in an ECT recovery room had the next lowest response rate (Rasmussen et al., 2013) . Diamond et al. (2014) is unique in that they assessed memory at baseline and after the treatment course, finding improvements in autobiographical, episodic, and subjective memory. This study was also the only one to directly compare different treatment regimens, though unexpectedly found better results with weekly versus twice weekly infusions.
Case Reports
The 17 published case studies (or judged equivalent) that utilized KET comprised just over 30 patients 
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Ryan, Marta, & Koek and-save for one dose finding study and another comparing racemic versus S-ketamine-typically utilized multiple infusions (Suppl. Table 1 ). These reports on 1-3 patients describe dramatic improvement in depressive symptoms and functioning in patients with TRD (Kollmar, Markovic, Thuerauf, Schmitt, & Kornhuber, 2008; Liebrenz, Borgeat, Leisinger, & Stohler, 2007; Liebrenz, Stohler, & Borgeat, 2009 ); antidepressant effect of ketamine even when this was only arrived at serendipitously (Ostroff, Gonzales, & Sanacora, 2005) ; several descriptions of prolonged relief of depression with repeated dosing (Correll, 2006; Messer et al., 2010; Murrough et al., 2011) ; and safe use of ketamine in depressed patients with severe medical comorbidities or who were concomitantly treated with multiple other CNS-acting medications (Kollmar et al., 2008; Liebrenz et al., 2007 Liebrenz et al., , 2009 Stefanczyk-Sapieha, Oneschuk, & Demas, 2008) . There were notable examples of rapid relief of intense dysphoria and crying in a terminally ill cancer patient on a palliative care unit (StefanczykSapieha et al., 2008) . The cases of Yang, Zhou, Gao, Shi, and Yang (2013) demonstrated rapid relief of depression in young, drug-naïve men. Szymkowicz, Finnegan, and Dale (2013) administered between 16-34 repeated KET infusions to three TRD patients over a 12 month period, adjusting frequency depending on individual response. Their first patient remitted after the 2nd infusion, and was maintained so with periodic treatments over the subsequent 9 months. Their two other subjects suffered repeated relapses despite intermittent courses of repeat infusions. Lai et al. (2014) is unique in that it is the only dose finding study, comparing 0.1 to 0.4mg/kg of ketamine IV over 5 minutes and a saline control, but due to low enrollment and poor retention, was placed with the cases. Only one of the four individuals displayed a clear dose response relationship for antidepressant response, though dissociative effects were clearly dose related.
Alternate Routes of Administration
In contrast to most studies of IV infusion, studies into intramuscular, subcutaneous, intranasal, oral, and sublingual dosing have mostly utilized multiple administrations attempting to extend response (Table  5) . Bioavailability of these different formulations ranges from ~20% for oral, ~30% for sublingual, 45% for intranasal, to 93% for intramuscular (Clements, Nimmo, & Grant, 1982) . Dose, frequency, follow up interval, treatment setting, and response metrics varied greatly between publications. All patients had their existing medications continued, potentially biasing results. Onset of benefit was generally rapid in parenteral routes, and was successfully maintained with repeat dosing in several instances.
In regards to IM administration, one OLI and five case studies detailed effects in 25 patients. The OLI study (Chilukuri et al., 2014) was notable in that it directly compared outcomes from different routes of administration (0.5mg/kg IV over 40 minutes, 0.25mg/ kg IM, and 0.5mg/kg IM) and found comparable response rates of 33-44% immediately and several days after administration. In contrast, in the case reports, doses ranged from 0.5mg/kg to 1.0mg/kg, from every 3-8 days, and from 2-68 treatments. The five patients with unipolar depression all met formal criteria for response by 24 hours. Glue, Gulati, Le Nedelec, and Duffull (2011) also performed a dose-response assessment finding greater improvements with higher doses; while 0.5mg/kg and 0.7mg/kg decreased MADRS scores, only 1.0mg/kg led to response. Glue (2012, 2013 ) described a woman with metastatic cancer and unipolar TRD who, after 1.0mg/kg, experienced remission of depression for 5-6 days, and pain for 24 hours. On a weekly outpatient regimen, response was largely maintained for 8 months. Two patients with bipolar depression experienced qualitative improvement within days to a week after 0.5mg/kg or 0.9mg/kg IM, that was maintained for 9-12 months by dosing at 3-4 day intervals, although one patient did require a dose increase after five months (Cusin, Hilton, Nierenberg, & Fava, 2012) .
Three studies utilized intranasal administration, of which one was a double blinded crossover RCT that compared ketamine 50mg with saline (Lapidus et al., 2014) . This study found significant differences in MADRS through two days, and a response rate of 44% at 24 hours, comparable to other RCTs that utilized ketamine infusions (Table 1; Figure 1 ). The second trial was a case series of 12 pediatric subjects (ages 6-19) with bipolar TRD that received a dose between 30-120mg. Onset of benefit was frequently within the hour, lasting for 3-4 days, and maintained for months with once to twice weekly dosing (Papolos et al., 2013) . The final case describes successful long term maintenance of euthymia with twice weekly intranasal administration.
The one study on sublingual administration, in a mixed cohort of unipolar and bipolar depression, utilized a 10mg dose and found "rapid" improvements Suicidality was assessed as a secondary or post-hoc measure; trials were designed to assess response rates for depression as the primary outcome measure.
[1] Patients overlap with Murrough et al. 2013 .
[2] Patients overlap with .
[5] Patients overlap between studies.
[3] Patients overlap between these studies.
[6] Data reported is for after completion of first infusion.
[4] Responders were randomized to riluzole or placebo, but upon analysis differences found to non-significant.
[7] Data reported is for after completion of all infusions.
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Ryan, Marta, & Koek up to three times daily [7] 21 days CGI yes, 10/14 (71%) [7] 5/6 (83%) had response start to fade at day 2-3 [7]
*Oral and Subcutaneous. ‡ Doses administered are racemic ketamine unless otherwise noted. † Avoidant Personality Disorder. All patients continued existing medications during treatment with ketamine.
[1] Includes follow-up publication on the same patient.
[5] Patient received a second course of treatment after initial relapse.
[2] Variable dose: 100 mg/mL solution via metered nasal spray pump bottle.
[6] An initial one time 0.5mg/kg (40 mg) subcutaneous dose was followed by 0.5mg/kg (40 mg) daily oral maintenance.
[3] Two patients overlap between these studies.
[7] Of 31 subjects, 29 received ketamine orally, 1 received subcutaneous, and 1 received via both routes; 22 received
[4] Two patients received 0.5mg/kg orally, which was titrated up in 0.5mg/kg increments at 1 dose, 5 received 2 doses, and 4 received three times daily dosing for 3 days; time to first response and time to follow-up sessions to final doses of 3.0mg/kg every 2-3 weeks and 1.5mg/kg monthly fading of response available for smaller sample.
Intramuscular Intranasal Sublingual Subcutaneous O/S* Oral
International Journal of Transpersonal Studies 51 Ketamine for Depression in 17 of the 26 patients, though the time frame was not defined. Using repeat dosing, from every 2-7 days, ten patients were described as maintaining response over a period of months, based on a Likert scale (Lara et al., 2013) .
Subcutaneous administration has also been reported on. McNulty et al. (2012) described a case of "dramatic relief" from depression in a hospice patient after initial subcutaneous administration of 0.5mg/ kg, followed by the same amount by mouth daily, with maintenance for 11 weeks. Another case describes long term maintenance of response with repeated doses, notably at only 0.2mg/kg (Gálvez et al., 2014) .
Oral, compared to parenteral, ketamine administration results in a higher blood norketamine to ketamine ratio because of extensive first pass metabolism. Norketamine is pharmacologically active as an NMDA antagonist and has analgesic and likely antidepressant effects. It has longer elimination half-life than ketamine itself. The clinical implications for treatment of depression are unclear (Blonk, Koder, van den Bemt, & Huygen, 2010) . We found four case studies and a subsequent OLI that utilized oral administration. One case study (Irwin & Iglewicz, 2010) in two hospice patients with depression found response in both after a single dose of 0.5mg/kg, one within 120 minutes, the other at 8 days. The follow-up OLI included 12 additional patients and utilized daily dosing of 0.5mg/kg (Irwin et al., 2013) , finding 57% response rate, mean time to response of 14.4 days, and maintenance of response for at least 28 days. Most recently the same authors published a retrospective chart review involving 31 patients finding 71% response at 24 hours after single oral doses of 0.5mg/kg (Iglewicz et al. 2014) . It is unclear why this study displayed such rapid response, while the other did not. De Gioannis and Leo (2014) described use of oral ketamine outside the hospice setting, in two individuals with bipolar disorder and suicidality, demonstrating maintenance of response with escalating doses of oral ketamine every two to four weeks.
S-Ketamine
Ketamine exists as a racemic mixture of the S-and R-stereoisomers, and while most studies have employed the racemate, a minority has solely used the more potent S-stereoisomer. There may be differences between the two, both in terms of antidepressant response and dissociative effects, though results are conflicting. Studies with S-ketamine describe treatment in just over ten patients, all with unipolar depression (Table 5, Suppl. Table 1) . No reports utilizing R-ketamine for treatment of depression exist. Only one publication, a case report, describes direct comparison between stereoisomeric forms of ketamine. Two patients were each given equianalgesic IV infusions of racemic ketamine 0.5mg/kg and S-ketamine 0.25mg/kg a week apart (Paul et al., 2009) . Robust antidepressant response to both isoforms of ketamine was observed in one patient, while the other responded to neither. Further, both patients had mild dissociative/perceptual disturbances ("psychotomimetic") with the racemate but not S-ketamine. Paslakis et al. (2010) treated four individuals with S-ketamine using a total oral daily dose of 1.25mg/kg, bioequivalent to 0.25mg/kg IV, divided over three times daily and similarly found no dissociative effects, and a 50% response rate. Conversely, subsequent studies utilizing IV infusions of S-ketamine 0.25mg/kg, either one time or multiple, found comparable response rates soon after infusion, but did note strong dissociative effects (Denk et al., 2011; Segmiller et al., 2013) .
Suicidality
The data regarding reduction of suicidality with ketamine is generally suggestive of benefit (Table 4) . The majority of studies did not assess suicidality as a primary outcome measure, and also utilized group mean change in suicidality scales rather than more easily interpretable results such as percent of the cohort achieving lack of suicidality. In regards to unipolar depression, three RCTs and nine OLIs reported on suicidality, typically utilizing either the HDRS or MADRS suicide items, or the scale for suicide ideation (SSI; Beck, Kovacs, & Weismann, 1979) . Of these, only one OLI reported lack of benefit. The others showed benefit at disparate time points ranging from the first four hours post dose to three days out. Time course data is present in only one study, with loss of significance after four hours. Four studies, however, reported categorical outcomes of percent of subjects attaining an SSI or MADRS-SI score below a certain threshold (resolution of suicidal thoughts). These "response rates" ranged from 81% to 90% within the first 24 hours. Another study found, at 4 hours, a 97% response rate in 33 previous ketamine responders, and a 100% response among the high suicidality subcohort (Diazgranados et al., 2010b) . Price et al. (2014) reanalyzed data from the Murrough et al. (2013) utilizing IV infusions (Murrough et al., 2011; Zigman & Blier 2013) , and a case series with IM administration (Harihar et al., 2013) , all showed benefit. Conversely, one OLI of oral ketamine in 14 hospice patients found no such benefit (Irwin et al., 2013) . In bipolar depression, two RCTs and two case series report on suicidality. The two RCTs, both by the same group, conflict in finding significant benefit. Zarate et al. (2012) demonstrated significant differences in between-group MADRS-SI scores through three days. Diazgranados et al. (2010a) , on the other hand, found no difference between IV ketamine and placebo, though these authors excluded patients with risk for suicide at baseline. One case series utilized IM administration and showed qualitative improvement (Cusin et al., 2012) , while the other did so with oral doses every two to four weeks (De Gioannis & Leo, 2014) .
Adverse Effects
During infusion, two adverse events with ketamine led to discontinuation in RCTs (Suppl. Table  2) : hypotension and bradycardia, and hypertension unresponsive to beta-blockers (Murrough et al., 2013) . Following infusion, four adverse events led to discontinuation: worsening mood in three patients (one with suicidal ideation), and increased anxiety in the other (Diazgranados et al., 2010a) . Two placebo patients discontinued, one each during infusion and after infusion for elevated blood pressure (Valentine et al., 2011) and hypomania (Diazgranados et al., 2010a) , respectively. In OLIs, only two adverse events led to treatment discontinuation out of nearly 300 individuals (Suppl . Table 3) : elevated blood pressure unresponsive to beta-blockers during infusion (Murrough et al., 2013) , and a panic attack (Diamond et al., 2014) . In case reports, one subject receiving S-ketamine at 0.25mg/ kg discontinued during infusion due to dissociation (Segmiller et al., 2013) .
Tachycardia and transient elevations in blood pressure were commonly reported hemodynamic effects in RCTs and OLIs, though two cases of hypotension (Murrough et al., 2013; aan het Rot et al., 2010) , one case of bradycardia (aan het , and one vasovagal episode were also reported. Aan het Rot et al. (2010) also reported one patient with bradypnea, with oxygen desaturation to 94%. To date, no RCTs or OLIs have reported these effects persisting beyond four hours, save for one patient with mild, asymptomatic hypotension lasting until discharge at 24 hours (aan het .
Dissociation, psychotomimetic effects, manic symptoms, and other psychiatric effects were assessed in most investigations. In RCTs and OLIs adverse effects In the four OLIs utilizing repeat dosing, changes in CADSS and BPRS were similar after each infusion, with no progressive increase with multiple infusions. Similarly, hemodynamic and respiratory effects did not worsen with repeat administrations. Dose dependent increases in dissociative symptoms were reported in one ascending dose study, in which rapid IV infusions over two to five minutes were used (Lai et al., 2014) . Transient tachycardia and asymptomatic premature ventricular contractions were described in one patient, and nausea and vomiting in another (aan het Shiroma et al., 2014) . One suicide attempt occurred during the washout period before ketamine infusion (Murrough et al., 2013) . One report of mania was found in a patient who received 34 doses of ketamine at variable intervals over a 1 year period (Liebrenz et al., 2009) , and another reported a "mild" hypomanic episode in a patient after his third infusion (Diamond et al., 2014) . Niciu et al. (2013) analyzed data from three NIMH RCTs of IV ketamine infusion in bipolar depression, finding transient increases in YMRS scores lasting no more than a day after infusion, and no cases of full blown mania or hypomania. They also reported that within the YMRS elevations, none of the patients had specific elevations in the elevated mood item (Suppl. Table 2) .
Adverse effects in case reports were consistent with those of RCTs and OLIs. Events uniquely described in the case reports include the following: less pronounced dissociation on a second dose compared to the first (Liebrenz et al., 2009; Clark et al., 2014) , hypomania in one patient (Szymkowicz et al., 2013) , "delirium" for 5-8 minutes following 0.5mg/kg bolus (Yang et al., 2013) , and in a report of two patients, psychotomimetic effects during racemic but not S-ketamine infusions (Szymkowicz et al., 2013) .
Intramuscular reports noted effects similar to those of IV, without mention of hemodynamic changes. In one case, decrease in dizziness and derealization occurred over repeat (41 total) injections (Zanicotti et al., 2013) , whereas in another a dose of 1.0mg/kg resulted in intolerable dissociative effects necessitating a dose decrease to 0.5mg/kg (Cusin et al., 2012) . In one intranasal study of 12 pediatric patients, transient (60 minutes) dissociative effects similar to IV were reported, as well as mild palpitations and moderate respiratory distress (Papolos et al., 2013) , whereas in another intranasal case report the patient described feeling "high," but only during the first few of more than thirty administrations (Clark et al., 2014) . Sublingual dosing in 26 patients resulted in no euphoria, psychotic, or dissociative symptoms. Lightheadedness (mild, transient, and improving on repeat dosing) and one report of tachycardia (<30 minutes) occurred. Mouth numbness was the only novel effect reported (Lara et al., 2013) . In the 50 patients that received oral ketamine, essentially no adverse effects, including vital sign changes, were reported (Paslakis et al., 2010; Irwin & Iglewicz, 2010; Irwin et al., 2013) , save for disorientation and hallucinations in a minority of a medically ill hospice population (Iglewicz et al., 2014) . In fact, there were improvements in BPRS and adverse symptom checklists (Irwin & Iglewicz, 2010) . Only diarrhea, trouble sleeping, and "trouble sitting still" occurred (one each) in a study of 14 patients (Irwin et al., 2013) . The only study of oral S-ketamine, divided over three times daily, found essentially no side effects in all four patients.
Ongoing and Planned Studies
A review of ClinicalTrials.gov yielded five OLIs and twenty RCTs (Table 6 ). Add-on oral medication as a potential method for extension of benefit is being investigated in a total of four studies: lithium, venlafaxine, minocycline, and d-cycloserine. Multiple dose regimens are being studied in nine trials, and suicidality is being studied in five. Four are assaying escalating doses, variable number of infusions, or increasing duration of infusion. The majority utilize ketamine IV infusions, while three are using intramuscular, intranasal, oral, or subcutaneous methods of administration. In only one study did we find a plan to include more than one route of administration. All studies utilize racemic ketamine. Discussion D iscussion is divided into consideration of antidepressant and antisuicidal effects, adverse effects, ketamine's stereoisomers, further clinical issues, and recommendations for future research.
Antidepressant and antisuicidal effects
Ketamine appears to have remarkably robust efficacy in short-term relief of severe and treatmentresistant depression, with onset in hours, and duration
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Ketamine for Depression of at least a few days. While this has been observed in both unipolar and bipolar depressed populations, in the latter, duration appears slightly shorter and there are fewer supporting studies. Similarly, in cases of non-TRD, this effect seems to hold, though relative efficacy is unclear. Ketamine's effectiveness in relief of acute suicidal ideation is also a highly valuable finding, though with less support. This benefit appears unique to ketamine among available treatment options, although comparisons with other active treatments are lacking. Furthermore, there are conflicting findings as to whether reductions in suicidality are specific, or rather related to overall reductions in depression (Price et al., 2009; Diazgranados et al., 2010b; Rasmussen et al., 2013; Murrough et al., 2013) . Studies for the most part have excluded individuals with recent suicidality, and instead performed post-hoc reanalyses of suicidality subscales, though future studies are enrolling high risk individuals for targeted therapy with ketamine (Table 6 ). To date there are no data on suicide attempts, completed suicide, or other long-term effects, nor on parasuicidal behavior. Despite the limited amount of data, this is fertile ground for further research given the great potential benefit to treat emergent suicidality or avert hospitalization. Ketamine deserves consideration for use in select patients who otherwise would continue to suffer severely, if only as a temporizing measure to give clinicians time to identify and implement alternative treatments.
The largest challenge with this promising agent remains the extension of benefit for the longer term, which is pertinent to the vast majority of depressed patients who have failed to benefit sufficiently from psychotherapy, psychosocial interventions, and the initial tiers of somatic intervention. Repeated ketamine infusions have shown some promise, and there may be a cumulative dose effect similar to ECT, where a series of treatments are required to induce full response or remission (aan het Murrough et al., 2013; Rasmussen et al., 2013) . Indeed, several studies concluded patients require more than one infusions before being considered non-responders. The comparison to ECT is tempting, and certainly makes for a good argument against those who would dismiss the potential for ketamine in depression because of the only short-term benefit of single infusions. It is far from clear what the optimum dose, frequency, and number of infusions will be, and how this might be individualized, though future studies will be revealing. It also worth noting that some patients do not benefit from ketamine, despite multiple treatments (Szymkowicz, Finnegan, & Dale, 2014) .
Alternatives to IV infusion, such as intramuscular (IM), intranasal(IN), oral, sublingual (SL), and subcutaneous (SC) routes, have been ástudied to a lesser extent, but do appear to work, with the trade-off of potentially lower response rates with all routes other than the IM, which results in ketamine bioavailability similar to IV administration. A significant limitation is lack of high quality prospective studies: of these alternate routes, our review found only one RCT, which utilized IN administration (Lapidus et al., 2014) . Compared with IV administration, IM, IN, and SL routes are similarly rapid acting, with conflicting and weaker data for SC and oral administrations. Duration of benefit is similar to IV infusions, on the order of days, but has been successfully prolonged with repeated dosing, which is notably easier given the relatively low resource requirements with such administrations. Several cases describe treatment in an office-based setting, with patients returning to the office anywhere from multiple times a week to once a month, and maintaining response on the order of months. It is unclear if such response eventually fades, or rather if it could be continued indefinitely, though several cases describe maintenance for nearly a year (Zanicotti et al., 2013; Cusin et al., 2012) . Oral dosing, while used mostly in hospice populations, appears to have slower onset of benefit, though an initial loading dose via a rapid acting route of administration could be combined with more convenient maintenance daily oral administration, as in one case report (McNulty et al., 2012) .
Adverse effects
Ketamine appears to be well tolerated, the most commonly reported adverse effects being transient dissociative and psychotomimetic experiences. As noted in several studies, patients appear to become tolerant to such effects after several subsequent administrations, and yet maintain a similar antidepressant response (Berman et al., 2000; Paul et al., 2009; Luckenbaugh et al., 2014) . Occasionally, hemodynamic effects, typically transient and mild, have led to treatment discontinuation although in every case these have responded to conservative management. There does not appear to be a correlation between hemodynamic effects and antidepressant response . In our review, sublingual, intranasal, and especially oral administration generally resulted in fewer adverse effects Ryan, Marta, & Koek than seen after IV administration, and may be due to a slower increase in blood levels (Lara et al., 2013; Paslakis et al., 2010; Irwin & Iglewicz, 2010; Irwin et al., 2013; Iglewicz et al., 2014) . Supporting this possibility, Lai et al. (2014) , found extensive dissociative symptoms with IV administration over 2 minutes, leading them to mitigate this issue by extending administration over five minutes. The safety profile of short-term ketamine, particularly in closely monitored settings, is reassuring.
There is however a relative paucity of data on ketamine's adverse effects in the long-term treatment of depression. Long-term exposure in abuse populations, where dose and frequency far exceed those used in clinical protocols, does suggest potentially serious sequelae. In such populations, both short-and longterm neurocognitive adverse effects have been reported (Curran & Monaghan, 2001; Morgan, Monaghan, & Curran, 2004) . Conversely, data from studies utilizing ketamine for treatment of depression indicate that it may actually improve neurocognitive outcomes, most likely by reversing the "pseudo-dementia" seen in severe depression (Permoda-Osip, Kisielewski, BartkowskaSniatkowska, & Rybakowski, 2015; Shiroma et al., 2014) . Lower urinary tract symptoms (LUTS) appear to be a not infrequent problem in long-term abusers of ketamine, and include urinary frequency, urge incontinence, dysuria, urgency, and hematuria (Chu et al., 2008; Shahani, Streutker, Dickson, & Stewart, 2007) . Severe sequelae have been reported including interstitial cystitis, papillary necrosis, and irreversible renal failure. In chronic pain patients and abusers, LUTS have been reported as early as five months, although symptoms may begin in as little as nine days (Chu et al., 2008; Storr & Quibell, 2009; Grégoire, Maclellan, & Finley, 2008) . One large prospective cohort study surveyed 3,806 recreational users, 1,285 of whom had used ketamine in the year prior. LUTS was reported in 340 (26.6%) in a dose and frequency related pattern. Resolution with abstinence occurred in 51% of cases, and continued deterioration occurred in 3.8% (Wein, 2013) . Mechanisms for these effects are unknown. In our review, only one complaint of urinary tract symptoms was found, cystitis, and judged to be caused not by ketamine, but rather sexual activity (Diamond et al., 2014) . Another setting in which ketamine's rapid onset of antidepressant-in addition to analgesic-effects has been used with success is the inpatient palliative care setting (Prommer et al., 2012 , Iglewicz et al., 2014 , though concern has been raised that in the cancer patients, ketamine's mTor upregulation could accelerate tumor growth (Yang, Zhou, & Yang, 2011) . In treatment of bipolar depression, another important adverse effect to monitor for is induction of mania or cycle acceleration. As noted in the review of three larger NIMH trials, this was not found to be a serious concern, however long-term data in this area are completely lacking.
Ketamine's Stereoisomers
Ketamine exists as a racemic mixture of the S-and R-stereoisomers, yet these appear to have subtly different effects. S-ketamine has long been known to have approximately 2-3 times greater potency in terms of analgesia and anesthesia (Kohrs & Durieux, 1998) , and 3-4 times greater affinity for the PCP binding site of the NMDA receptor, but only negligible binding to the sigma receptor. R-ketamine on the other hand, has greater, although still weak, sigma receptor binding, but the significance of this is unclear (Vollenweider, Leenders, Oye, Hell, & Angst, 1997) . Observations from the anesthesia literature initially noted that in equianalgesic doses, S-ketamine has a lower incidence of psychotomimetic side effects than either the racemate or R-stereoisomer (Raeder et al., 2000) , leading some to investigate it for depression. Both the racemate and S-ketamine appear to have antidepressant effects, but data regarding psychotomimetic effects of the component stereoisomers are more contradictory. A separate series of trials may perhaps explain this; one pilot study of healthy individuals found that the dose of S-ketamine required to induce psychosis is 60% of that of the racemate, suggesting the S-enantiomer is responsible for such effects (Vollenweider et al., 1997) . These authors found psychotomimetic effects in S-ketamine versus "a state of relaxation" in R-ketamine (Vollenweider et al., 1997) . Animal studies assessing equimolar equivalents of each stereoisomer found both to provide a rapid and long lasting antidepressant effect, but ultimately a longer durability of effect with the R-enantiomer, leading them to speculate the R-form may be a good candidate for future study (Zhang, Li, & Hashimoto, 2014; Hashimoto et al., 2014) . Further research directly comparing S-, R-, and racemic ketamine is needed to clarify if one indeed exhibits fewer dissociative effects while still maintaining antidepressant efficacy.
Further Clinical Issues
There is no uniform definition of treatment resistance in the literature reviewed, although patients
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Ketamine for Depression with or without treatment resistance, however defined, respond similarly. In assessing improvements in depression, the most commonly used measures-the MADRS and HDRS-may not adequately assess change over a time scale on the order of hours. Several questions, for example regarding sleep and appetite, cannot reflect change over the course of a 40 minute infusion; some studies have gotten around this by carrying forward prior subscores (Rasmussen et al., 2013) . The issue of concomitant medications-or their discontinuationis another confound which will need to be carefully managed in the design of future long term studies.
Several potential predictors of response have received attention. Our review suggests that both bipolar and unipolar depressed patients may exhibit short term response to ketamine. Besides the potential for pharmacologic differences between the S-and Renantiomers discussed above, ketamine is hepatically metabolized to norketamine, which also has neurotrophic effects and psychopharmacologic properties. The importance of this is unclear; Sos et al. (2013) found no correlation between blood levels of ketamine or norketamine and antidepressant response. Several authors have suggested that the melancholic subtype of major depression may augur a greater likelihood of response, but this not been studied prospectively (Paslakis et al., 2010; Atigari & Healy, 2013; Gálvez et al., 2014) . Multiple studies found a greater likelihood of antidepressant response in TRD patients with a family history of alcoholism, compared to those without, although no relationship to personal history of alcoholism was seen (Phelps et al., 2009; . found greater response in anxious versus non-anxious unipolar depression, but in a separate posthoc analysis in bipolar depression found no difference between the anxious and non-anxious subtypes. At least in bipolar depression, this is notable because those with the anxious subtype are frequently poorer responders to conventional treatment. To this end, in studies of conditions previously classified as anxiety disorders, such as post-traumatic stress disorder and obsessivecompulsive disorder, ketamine has also shown benefit (Feder et al., 2014; Rodriguez et al., 2013) .
To date, other agents directed at the neurochemical system most frequently held to account for ketamine's antidepressant effect-NMDA receptor antagonism-have been disappointing in terms of extending ketamine's short-term benefits (Ibrahim et al., 2012; Mathew et al., 2010; Zarate et al., 2006; HerescoLevy et al., 2006) . Additional trials are underway to explore this strategy, although infusion of a specific NMDA antagonist, AZD6765, was not effective . Alternative mechanisms, such as ketamine's effects on seizure threshold, are worth considering (Atigari & Healy, 2013 ).
An obvious question is how dissociative and antidepressant effects might be related. Our review found that the time course of these effects differs substantially, and antidepressant effects can occur in patients who do not experience even transient dissociative effects and vice-versa. One post-hoc analysis found that magnitude of acute dissociative symptoms partially correlated with later antidepressant response . Thus, the dissociative effects are not necessarily part of the antidepressant effects per se. On the other hand, it is worth considering that this dissociation is part of the unique effect of ketamine that is not shared by conventional antidepressants: an altered sense of self that can also lead to a new state of contentment. This could explain why recent trials with non-psychoactive NDMA antagonists have not demonstrated antidepressant efficacy, and may in fact represent an as yet unexplored aspect of mood regulation-what might be called the eudaimonic dimension ( or "well-being," from Aristotle)-that ketamine has given the field an opening to better explore. Companion articles in this current issue expand on this notion in much more depth. It is also worth noting that nitrous oxide and classic hallucinogens, share similar dissociative/psychotomimetic and antidepressant effects with ketamine (Nagele et al., 2014; Baumeister, Barnes, Giaroli, & Tracy, 2014) . Similarly, ketamine and the classic hallucinogens have each been employed in end of life care, either for depression or anxiety, but perhaps with a similar mechanism (Iglewicz et al., 2014; Gasser et al., 2014; Grob et al., 2011) . It may be the case, as with classic hallucinogens, which were originally termed psychotomimetic, that these altered states are less "psychotic mimicking" and more psychedelic, or "mind manifesting." In the case of classic hallucinogens, concerns over these effects led their potential antidepressant benefit to be ignored for many years (Baumeister et al., 2014) .
A corollary issue pertinent to ketamine's unique effects is what has been called "set and setting" (Johnson, Richards, & Griffiths, 2008) . That is, the mind sets of the provider and the patient, and the Ryan, Marta, & Koek environmental setting in which the treatment session occurs, may have particularly important impact on treatment outcome. Consistent with this, two studies conducted in noisy, crowded, high intensity medical settings had the poorest outcomes among the studies of multiple ketamine infusions (Rasmussen et al., 2013; Diamond et al., 2014) . Conversely, recent studies of MDMA-assisted psychotherapy for post-traumatic stress disorder (Mithoefer et al., 2013) and psilocybin for end of life anxiety (Grob et al., 2011) used carefully designed protocols to optimize these aspects of the interventions. It is possible that similar optimization of ketamine treatment would improve antidepressant outcomes.
Several unanswered questions remain in the clinical use of ketamine for depression. Is the presence of an anesthesiologist required? By extending the duration of the ketamine infusion to 100 minutes anesthesiology monitoring was determined to be unnecessary (Rasmussen et al., 2013) . Another study reports infusions were performed by a psychiatrist with Basic Life Support training and code team backup (Zigman & Blier, 2013) . A further question, as alluded to in discussion of alternate routes, is whether ketamine could be used in an office-based setting: the RCT using intranasal ketamine amended their protocol after demonstrated safety, and began discharging individuals four hours after receiving their doses (Lapidus et al., 2014) . Furthermore, several case reports utilizing IM and other methods of administration describe successful long-term treatment in an office-based setting. Ultimately, more rigorous studies in such settings are needed.
Ketamine has not yet been formally promoted for general clinical use but has seen growing use among psychiatrists in private practice and academic centers. Providers hoping to utilize ketamine for treatment of depression should take care to offer full informed consent as well as communicate that this use is off-label from FDA approved indications of ketamine. There is a relative paucity of data on both the effectiveness and safety in the outpatient setting, though case reports suggest this can successfully be done. Existence of an abuse population must also be considered when expanding ketamine use to this setting. Further, there are serious safety concerns from the abuse and pain management literature, as noted above. Our review provides strong suggestive support for the use of more "user friendly" alternatives to IV infusion, but caution is warranted.
Recommendations for future research
Based on this review, the following specific recommendations stand out: 1) Trials to further assess if benefit seen in TRD extends to non-treatment refractory depression. 2) Direct comparisons between various routes of administration, both in acute and maintenance treatment, as well as to both placebo or standard agents. 4) Trials to specifically assess anti-suicidal effects, in both acute and maintenance treatment. 5) Dose-response relationships for each route of administration, including monitoring of levels of both ketamine and norketamine levels. 6) Examination of optimal dosing frequencies for all routes of administration, with the goal of extending duration of response 7) Systematic monitoring of psychotomimetic and dissociative effects with long-term treatment, and correlations with responses to treatment, including whether tachyphylaxis to these effects may occur. 8) Systematic monitoring of neuropsychological functions, urinary tract related symptoms, suicidal behavior, and at least in bipolar subjects, mood switching, during long term treatment. 9) Careful analysis of ketamine's "eudaimonic" effects as they relate to antidepressant, dissociative, psychotomimetic, and antisuicidality effects. 10) Additional trials to follow-up on the suggested benefits of ketamine in other disorders such as PTSD and OCD; and as a transpersonal agent for those with life threatening illness and at the end-of life.
Conclusion
A thorough review of the literature utilizing ketamine for treatment refractory depression reveals rapid onset of action in the first several hours, often lasting several days to a week, after a single infusion. We acknowledge a common criticism raised about the limited time frame of efficacy from a single dose of ketamine, however this does not distinguish it from any other treatment of depression, including psychotherapy, medication, or ECT. Furthermore, multiple dosing studies and alternate routes of administration have safely and successfully extended the antidepressant benefit of ketamine, with select cases demonstrating maintenance for nearly a year. These findings are all
International Journal of Transpersonal Studies 59
Ketamine for Depression the more impressive when viewed from the perspective of an already treatment-resistant population. While the existing paradigm of 40 minute IV infusions has proven limitedly effective, much less resource intensive protocols such as intranasal, intramuscular, oral, and subcutaneous methods of administration represent a potential revolution in the use of ketamine. These routes of administration have the advantage of expanding ketamine research to the outpatient setting. We did not find evidence of serious neurocognitive adverse effects in clinical use, in contrast to what has been reported with ketamine abuse. This is an area in which ketamine may distinguish itself from ECT as an alternative for TRD. Similarly, we did not find evidence of LUTS, but this has not been systematically investigated. The frequency and seriousness of LUTS in the abuse population makes it an important adverse effect to monitor in future long term studies.Dissociative effects are common, time limited, generally well tolerated, and appear to subside in intensity with repeat dosing. These and other unique effects, distinguish it from currently used monoaminergic antidepressants and warrant further study in terms of their ability to advance understanding of depression and its treatment. Significant hemodynamic effects requiring intervention are possible but uncommon, and do require careful monitoring. Potential contraindications do exist, including psychosis, abuse liability, and hemodynamic instability, but with care in patient selection unwanted outcomes can be minimized. Ketamine is clearly a very promising agent. While we must urge caution in wide spread clinical application before further research is completed, our review of the risks and benefits supports its use in carefully selected cases who have not benefited from other treatments. n/a 1-3 days n/a n/a 1 day
[2] Subjects received ascending doses of ketamine, from 0.1 -0.4mg/kg, interspersed with a saline treatment. Patients were blinded to the order. [1] 6 infusions total, 3x/wk for 2wks;
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[2] Reported over 28 days and compared between post treatment with riluzole or placebo.
[3] up to 4 infusions total, 2x/wk for 2 wks or until remission.
